Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.

Zacks Investment Research • 6 hours ago

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:  CPRX ) related to its sale to Angelini Pharma S.p.A. Under the terms of the proposed transaction Catalyst shareholders are expected to receive $31.50 per share in cash. Is it a fair deal?

GlobeNewsWire • May 11, 2026

Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results

Delivered Q1 2026 Total Revenues  of $149.4 Million Results include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026

GlobeNewsWire • May 11, 2026

Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.68 per share a year ago.

Zacks Investment Research • a day ago

Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • a day ago

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led to it.

Business Wire • May 10, 2026

Italy's Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion

Italy's ​Angelini ‌Pharma ​said ​on ⁠Thursday ​it ​has agreed ​to ​acquire Catalyst ‌Pharmaceuticals ⁠for $4.1 ​billion.

Reuters • May 7, 2026

Catalyst Pharma to Be Acquired by Angelini Pharma in $4.1 Billion Deal

The move marks Italy's Angelini Pharma's entry into the U.S. market.

WSJ • May 7, 2026

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026 The transaction marks Angelini Pharma's entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026 ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.

GlobeNewsWire • May 7, 2026

Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A.

GlobeNewsWire • May 7, 2026